Retinal Degeneration: Clinical Trials

2,018 trials for Retinal Degeneration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1132 completed, 253 unknown, 198 recruiting, 187 terminated. 499 Phase 2, 387 Not applicable, 330 Phase 1, 282 Phase 3, 153 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2499Completed 259, Terminated 73, Unknown 53, Recruiting 49, Active not recruiting 34, Withdrawn 16, Not yet recruiting 11, Enrolling by invitation 4
Not applicable387Completed 201, Unknown 66, Recruiting 43, Terminated 26, Not yet recruiting 19, Withdrawn 17, Active not recruiting 11, Enrolling by invitation 4
Phase 1330Completed 178, Recruiting 48, Unknown 33, Active not recruiting 28, Terminated 28, Not yet recruiting 7, Withdrawn 6, Enrolling by invitation 1, Suspended 1
Phase 3282Completed 168, Terminated 33, Unknown 32, Recruiting 15, Active not recruiting 14, Not yet recruiting 9, Withdrawn 9, Enrolling by invitation 1, Suspended 1
Phase 4153Completed 103, Unknown 23, Terminated 14, Withdrawn 5, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1
Early Phase 125Recruiting 9, Unknown 6, Completed 5, Not yet recruiting 3, Active not recruiting 1, Withdrawn 1

Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss
Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping - Macular Degeneration, Central Visual Impairment
Not applicableNot yet recruitingUniversity of Minnesota2162027-06-012026-10-29
GA001 Injection in Retinitis Pigmentosa
GA001, Sham injection - Retinitis Pigmentosa (RP)
Phase 2Not yet recruitingGenAns Biotechnology Co., Ltd122027-04-012026-11-17
Safety and Clinical Performance of the LENTISĀ® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
Intraocular Lens - Cataract, AMD - Age-Related Macular Degeneration
Not applicableNot yet recruitingTeleon Surgical B.V.352027-02-012026-11-04
Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa
Not applicableNot yet recruitingUniversity of Southern California52027-01-102026-01-08
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
Not yet recruitingIRCCS San Raffaele1602027-01-022026-09-29
Prevalence of Age-Related Macular Degeneration in Assiut University Hospitals
OCT - clear - Age-Related Macular Degeneration (AMD)
Not yet recruitingAssiut University902027-01-012026-10-21
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3Not yet recruitingNacuity Pharmaceuticals, Inc.802026-12-012026-07-01
Njinsky Ambispective Cellular Product Safety and Outcomes Registry
Umbilical Cord Mesenchymal Stem Cells, Stromal Vascular fraction - Retinitis Pigmentosa (RP), Autism Disorder
Not yet recruitingNjinsky Medical Centre12002026-12-012026-11-17
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography - Geographic Atrophy
Not applicableEnrolling by invitationUniversity of Wisconsin, Madison102026-11-052026-10-26
MacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration
Transpalpebral microcurrent electrical stimulation - Age-Related Macular Degeneration (AMD)
Not applicableNot yet recruitingClarity Eye Institute502026-11-042026-11-04
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
CITY-RBP4, Placebo - Stargardt Disease 1, STGD1
Phase 1RecruitingCity Therapeutics482026-11-042026-11-12
OCT Macula Biomarkers Before Silicone Oil Removal and Visual Outcome After Silicone Oil Removal
Retinal Detachment, Macular Edema
Not yet recruitingAssiut University302026-11-012026-10-08
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID, Placebo 2drops TID - wetAMD, Age Related Macular Degeneration
Phase 2Not yet recruitingSCAI Therapeutics502026-11-012026-05-26
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Active hf-tRNS., Placebo/sham hf-tRNS - Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Not applicableRecruitingUniversity of Waterloo202026-11-012026-11-03
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD)
Phase 2Not yet recruitingEverest Medicines (China) Co.,Ltd.2442026-11-012026-11-05
A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
1 % Bevemipretide, 2% Bevemipretide, Vehicle - Dry AMD, Age-Related Macular Degeneration (AMD)
Phase 2 / Phase 3Not yet recruitingMighty Therapeutics, Inc.3002026-11-012026-11-09
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3RecruitingNacuity Pharmaceuticals, Inc.802026-10-232026-11-10
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
OLN324, Ranibizumab - Wet Age-related Macular Degeneration
Phase 3Not yet recruitingOllin Biosciences, Inc.4002026-10-152026-09-11
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
OLN324, Aflibercept - Wet Age Related Macular Degeneration
Phase 3Not yet recruitingOllin Biosciences, Inc.5002026-10-152026-09-11
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
Photobiomodulation Therapy, Sham Photobiomodulation - AMD - Age-Related Macular Degeneration
Not applicableRecruitingFondazione G.B. Bietti, IRCCS672026-10-092026-11-16

Showing 20 of 2018. Sign in to see all of them.

Narrower conditions

Macular Degeneration (1174)  ·  Macular Edema (418)  ·  Retinitis Pigmentosa (270)  ·  Geographic Atrophy (179)  ·  Diabetic Retinopathy (160)  ·  Retinal Vein Occlusion (155)  ·  Choroidal Neovascularization (138)  ·  Retinal Diseases (136)  ·  Eye Diseases (99)  ·  Wet Macular Degeneration (93)  ·  Vision Disorders (89)  ·  Diabetes Mellitus (66)  ·  Stargardt Disease (66)  ·  Glaucoma (52)

Broader conditions

Eye Diseases (1919)  ·  Retinal Diseases (1882)  ·  Macular Degeneration (527)  ·  Eye Diseases, Hereditary (424)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (382)  ·  Genetic Diseases, Inborn (371)  ·  Pathological Conditions, Signs and Symptoms (371)  ·  Cardiovascular Diseases (308)  ·  Vascular Diseases (307)  ·  Retinal Dystrophies (279)  ·  Nervous System Diseases (219)  ·  Uveal Diseases (218)  ·  Endocrine System Diseases (208)  ·  Pathologic Processes (199)

Interventions

Ranibizumab (263)  ·  aflibercept (151)  ·  Bevacizumab (81)  ·  salicylhydroxamic acid (63)  ·  Dexamethasone (51)  ·  Calcium Dobesilate (40)  ·  Triamcinolone Acetonide (34)  ·  Verteporfin (32)  ·  pegaptanib (26)  ·  brolucizumab (22)  ·  Triamcinolone (21)  ·  Tomography, Optical Coherence (18)  ·  Lutein (15)  ·  Photochemotherapy (14)  ·  Intravitreal Injections (13)

Sponsors

National Eye Institute (NEI) (90)  ·  Novartis Pharmaceuticals (67)  ·  Allergan (38)  ·  Bayer (38)  ·  Medical University of Vienna (28)  ·  Genentech, Inc. (26)  ·  Johns Hopkins University (25)  ·  Notal Vision Ltd. (21)  ·  Alcon Research (20)  ·  Hoffmann-La Roche (16)  ·  Pfizer (16)  ·  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (15)  ·  Duke University (14)  ·  University of Sao Paulo (13)  ·  GlaxoSmithKline (12)

Countries

United States (909)  ·  France (192)  ·  Germany (189)  ·  United Kingdom (176)  ·  Canada (134)  ·  Italy (130)  ·  China (114)  ·  Australia (113)  ·  Austria (104)  ·  Spain (104)  ·  Israel (89)  ·  Hungary (72)  ·  Switzerland (71)  ·  Poland (65)  ·  South Korea (64)

Top investigators

Emily Y Chew, M.D. (9)  ·  Pablo Velazquez-Martin, MD (8)  ·  Peter A Campochiaro, MD (6)  ·  Jennifer Henrick, RN, MS (5)  ·  Mohamed Genead, MD (5)  ·  Peter Campochiaro, MD (5)

Results publications

PMID 37314061, PMID 37702300, PMID 32374423, PMID 32573764, PMID 40547876, PMID 22281388, PMID 25458728, PMID 30957581, PMID 32844399, PMID 34934034, PMID 39758130, PMID 23049090, PMID 23084240, PMID 23706949, PMID 25677668, PMID 30194931, PMID 33206392, PMID 33331670, PMID 35085502, PMID 36246941, PMID 36912792, PMID 37261916, PMID 39102242, PMID 39207600, PMID 11297486, PMID 15808240, PMID 17021318, PMID 17021319, PMID 19255158, PMID 19365036, PMID 19506188, PMID 20189654, PMID 20378094, PMID 20683380, PMID 20688734, PMID 20920825, PMID 21296824, PMID 21320967, PMID 21546089, PMID 21794843, PMID 22234714, PMID 22559899, PMID 22562517, PMID 22761263, PMID 22965590, PMID 23009891, PMID 23361508, PMID 23415775, PMID 23453513, PMID 23668681

NIH funding

2014 (12), 2019 (11), 2018 (7), 2025 (6), 2009 (5), 2017 (5), 2015 (4), 2016 (4), 2005 (2), U10EY014231 (2), U10EY018817 (2), U10EY024527 (2), 1UG1EY033293 (1), 2023 (1), I01RX004563 (1)